-
1
-
-
0019378211
-
Increased incidence of acute leukemia in polycy-themia vera associated with chlorambucil therapy
-
Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycy-themia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-447.
-
(1981)
N Engl J Med
, vol.304
, Issue.8
, pp. 441-447
-
-
Berk, P.D.1
Goldberg, J.D.2
Silverstein, M.N.3
-
2
-
-
20144389274
-
Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study
-
DOI 10.1182/blood-2004-09-3426
-
Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670. (Pubitemid 40446255)
-
(2005)
Blood
, vol.105
, Issue.7
, pp. 2664-2670
-
-
Finazzi, G.1
Caruso, V.2
Marchioli, R.3
Capnist, G.4
Chisesi, T.5
Finelli, C.6
Gugliotta, L.7
Landolfi, R.8
Kutti, J.9
Gisslinger, H.10
Marilus, R.11
Patrono, C.12
Pogliani, E.M.13
Randi, M.L.14
Villegas, A.15
Tognoni, G.16
Barbui, T.17
-
3
-
-
33745714754
-
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia
-
Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 2006;32(4 Pt 2):417-421.
-
(2006)
Semin Thromb Hemost
, vol.32
, Issue.4 PART 2
, pp. 417-421
-
-
Kiladjian, J.J.1
Rain, J.D.2
Bernard, J.F.3
Briere, J.4
Chomienne, C.5
Fenaux, P.6
-
4
-
-
72849140307
-
Risk stratification for survival and clonal progression in essential thrombocythemia (ET): Result of a prospective study of 108 patients with very long term follow up
-
[abstract]. Abstract 1747
-
Kiladjian J-J, Chevret S, Abgrall J-F, Chait Y, Briere J. Risk stratification for survival and clonal progression in essential thrombocythemia (ET): result of a prospective study of 108 patients with very long term follow up [abstract]. Blood. 2008;112(11):Abstract 1747.
-
(2008)
Blood
, vol.112
, pp. 11
-
-
Kiladjian, J.-J.1
Chevret, S.2
Abgrall, J.-F.3
Chait, Y.4
Briere, J.5
-
5
-
-
23844483519
-
Leukemic transformation of polycythemia vera: A single center study of 23 patients
-
DOI 10.1002/cncr.21297
-
Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104(5):1032-1036. (Pubitemid 41170231)
-
(2005)
Cancer
, vol.104
, Issue.5
, pp. 1032-1036
-
-
Passamonti, F.1
Rumi, E.2
Arcaini, L.3
Castagnola, C.4
Lunghi, M.5
Bernasconi, P.6
Della Porta, M.G.7
Columbo, N.8
Pascutto, C.9
Cazzola, M.10
Lazzarino, M.11
-
6
-
-
73949151305
-
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
-
Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
-
(2009)
J Clin Oncol
, vol.27
, Issue.33
, pp. 5587-5593
-
-
Tam, C.S.1
Kantarjian, H.2
Cortes, J.3
-
7
-
-
60849089645
-
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
-
Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315-1325.
-
(2009)
Blood
, vol.113
, Issue.6
, pp. 1315-1325
-
-
Jiang, Y.1
Dunbar, A.2
Gondek, L.P.3
-
8
-
-
0036008494
-
INK4ain agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation
-
DOI 10.1046/j.0007-1048.2001.03319.x
-
Wang JC, Chen W, Nallusamy S, Chen C, Novetsky AD. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol. 2002;116(3):582-586. (Pubitemid 34178657)
-
(2002)
British Journal of Haematology
, vol.116
, Issue.3
, pp. 582-586
-
-
Wang, J.C.1
Chen, W.2
Nallusamy, S.3
Chen, C.4
Novetsky, A.D.5
-
9
-
-
0037093195
-
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
-
DOI 10.1200/JCO.2002.04.117
-
Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440. (Pubitemid 34525728)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.10
, pp. 2429-2440
-
-
Silverman, L.R.1
Demakos, E.P.2
Peterson, B.L.3
Kornblith, A.B.4
Holland, J.C.5
Odchimar-Reissig, R.6
Stone, R.M.7
Nelson, D.8
Powell, B.L.9
DeCastro, C.M.10
Ellerton, J.11
Larson, R.A.12
Schiffer, C.A.13
Holland, J.F.14
-
10
-
-
62849104641
-
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study
-
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
-
(2009)
Lancet Oncol
, vol.10
, Issue.3
, pp. 223-232
-
-
Fenaux, P.1
Mufti, G.J.2
Hellstrom-Lindberg, E.3
-
11
-
-
43749117734
-
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
-
DOI 10.1038/leu.2008.91, PII LEU200891
-
Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/ polycythemia vera myelofibrosis. Leukemia. 2008;22(5):965-970. (Pubitemid 351689878)
-
(2008)
Leukemia
, vol.22
, Issue.5
, pp. 965-970
-
-
Quintas-Cardama, A.1
Tong, W.2
Kantarjian, H.3
Thomas, D.4
Ravandi, F.5
Kornblau, S.6
Manshouri, T.7
Cortes, J.E.8
Garcia-Manero, G.9
Verstovsek, S.10
-
12
-
-
58249096418
-
5-Azacitidine has limited therapeutic activity in myelofibrosis
-
Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia. 2009;23(1):180-182.
-
(2009)
Leukemia
, vol.23
, Issue.1
, pp. 180-182
-
-
Mesa, R.A.1
Verstovsek, S.2
Rivera, C.3
-
13
-
-
70349256226
-
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
-
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
-
(2009)
Blood
, vol.114
, Issue.5
, pp. 937-951
-
-
Vardiman, J.W.1
Thiele, J.2
Arber, D.A.3
-
14
-
-
0019952276
-
Proposals for the classification of the myelodysplastic syndromes
-
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
-
(1982)
Br J Haematol
, vol.51
, Issue.2
, pp. 189-199
-
-
Bennett, J.M.1
Catovsky, D.2
Daniel, M.T.3
-
15
-
-
0016776911
-
Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia
-
Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol. 1975;12(4):409-432.
-
(1975)
Semin Hematol
, vol.12
, Issue.4
, pp. 409-432
-
-
Laszlo, J.1
-
16
-
-
0016793754
-
Diagnosis and classification of the polycythemias
-
Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-351.
-
(1975)
Semin Hematol
, vol.12
, Issue.4
, pp. 339-351
-
-
Berlin, N.I.1
-
17
-
-
0036786901
-
The World Health Organization (WHO) classification of the myeloid neoplasms
-
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
-
(2002)
Blood
, vol.100
, Issue.7
, pp. 2292-2302
-
-
Vardiman, J.W.1
Harris, N.L.2
Brunning, R.D.3
-
18
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
19
-
-
1542753559
-
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
-
Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
-
(2003)
J Clin Oncol
, vol.21
, Issue.24
, pp. 4642-4649
-
-
Cheson, B.D.1
Bennett, J.M.2
Kopecky, K.J.3
-
20
-
-
73949151305
-
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
-
Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009;27(33):5587-5593.
-
(2009)
J Clin Oncol
, vol.27
, Issue.33
, pp. 5587-5593
-
-
Tam, C.S.1
Kantarjian, H.2
Cortes, J.3
-
21
-
-
33845382806
-
Non parametric estimation from incomplete observation
-
Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assos. 1958;53:457.
-
(1958)
J Am Stat Assos
, vol.53
, pp. 457
-
-
Kaplan, E.1
Meier, P.2
-
22
-
-
0000336139
-
Regression models and life-tables (with discussion)
-
Cox D. Regression models and life-tables (with discussion). J R Stat Soc B. 1972;34:487.
-
(1972)
J R Stat Soc B
, vol.34
, pp. 487
-
-
Cox, D.1
-
23
-
-
33646071894
-
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
-
Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
-
(2006)
Cancer
, vol.106
, Issue.8
, pp. 1794-1803
-
-
Kantarjian, H.1
Issa, J.P.2
Rosenfeld, C.S.3
-
24
-
-
0025778623
-
Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients
-
Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 1991;85(3):124-127.
-
(1991)
Acta Haematol
, vol.85
, Issue.3
, pp. 124-127
-
-
Cervantes, F.1
Tassies, D.2
Salgado, C.3
Rovira, M.4
Pereira, A.5
Rozman, C.6
-
25
-
-
12844284481
-
Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases
-
DOI 10.1182/blood-2004-07-2864
-
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977. (Pubitemid 40170863)
-
(2005)
Blood
, vol.105
, Issue.3
, pp. 973-977
-
-
Mesa, R.A.1
Li, C.-Y.2
Ketterling, R.P.3
Schroeder, G.S.4
Knudson, R.A.5
Tefferi, A.6
-
26
-
-
52649131772
-
The natural history and treatment outcome of blast phase BCR-ABL- Myeloproliferative neoplasms
-
Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
-
(2008)
Blood
, vol.112
, Issue.5
, pp. 1628-1637
-
-
Tam, C.S.1
Nussenzveig, R.M.2
Popat, U.3
-
27
-
-
16944363756
-
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
-
Kantarjian HM, O'Brien SM, Keating M, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11(10):1617-1620. (Pubitemid 27458597)
-
(1997)
Leukemia
, vol.11
, Issue.10
, pp. 1617-1620
-
-
Kantarjian, H.M.1
O'Brien, S.M.2
Keating, M.3
Beran, M.4
Estey, E.5
Giralt, S.6
Kornblau, S.7
Rios, M.B.8
De Vos, D.9
Talpaz, M.10
-
28
-
-
0033572876
-
Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
-
DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0. CO;2-A
-
Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86(12):2632-2641. (Pubitemid 30004667)
-
(1999)
Cancer
, vol.86
, Issue.12
, pp. 2632-2641
-
-
Sacchi, S.1
Kantarjian, H.M.2
O'Brien, S.3
Cortes, J.4
Rios, M.B.5
Giles, F.J.6
Beran, M.7
Koller, C.A.8
Keating, M.J.9
Talpaz, M.10
-
29
-
-
33644846509
-
Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction?
-
Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107-116.
-
(2006)
Nat Rev Cancer
, vol.6
, Issue.2
, pp. 107-116
-
-
Baylin, S.B.1
Ohm, J.E.2
-
30
-
-
20144366960
-
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
-
DOI 10.1038/ng1521
-
Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 2005;37(3):265-274. (Pubitemid 41716253)
-
(2005)
Nature Genetics
, vol.37
, Issue.3
, pp. 265-274
-
-
Yu, L.1
Liu, C.2
Vandeusen, J.3
Becknell, B.4
Dai, Z.5
Wu, Y.-Z.6
Raval, A.7
Liu, T.-H.8
Ding, W.9
Mao, C.10
Liu, S.11
Smith, L.T.12
Lee, S.13
Rassenti, L.14
Marcucci, G.15
Byrd, J.16
Caligiuri, M.A.17
Plass, C.18
-
31
-
-
42249115029
-
Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders
-
DOI 10.1111/j.1365-2141.2008.07072.x
-
Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008;141(4):504-511. (Pubitemid 351550557)
-
(2008)
British Journal of Haematology
, vol.141
, Issue.4
, pp. 504-511
-
-
Capello, D.1
Deambrogi, C.2
Rossi, D.3
Lischetti, T.4
Piranda, D.5
Cerri, M.6
Spina, V.7
Rasi, S.8
Gaidano, G.9
Lunghi, M.10
-
32
-
-
33847223121
-
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders
-
DOI 10.1038/sj.leu.2404513, PII 2404513
-
Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21(3):505-510. (Pubitemid 46306562)
-
(2007)
Leukemia
, vol.21
, Issue.3
, pp. 505-510
-
-
Jost, E.1
Do O, N.2
Dahl, E.3
Maintz, C.E.4
Jousten, P.5
Habets, L.6
Wilop, S.7
Herman, J.G.8
Osieka, R.9
Galm, O.10
-
33
-
-
55549126446
-
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders
-
Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93(11):1635-1644.
-
(2008)
Haematologica
, vol.93
, Issue.11
, pp. 1635-1644
-
-
Fourouclas, N.1
Li, J.2
Gilby, D.C.3
-
34
-
-
55049114480
-
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis
-
Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells. 2008;26(8):1920-1930.
-
(2008)
Stem Cells
, vol.26
, Issue.8
, pp. 1920-1930
-
-
Bogani, C.1
Ponziani, V.2
Guglielmelli, P.3
-
35
-
-
70349975711
-
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin
-
Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461(7265):819-822.
-
(2009)
Nature
, vol.461
, Issue.7265
, pp. 819-822
-
-
Dawson, M.A.1
Bannister, A.J.2
Gottgens, B.3
|